According to filings with the U.S. Securities and Exchange Commission, Oral Genome is raising up to $5,107,595.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Oral Genome
Oral Genome was founded by a dentist who was on a mission to help provide her patients with quality comprehensive dental care with a focus on prevention. Oral Genome seeks to empower people to optimize their oral health and attain a healthy and happy smile for life. Oral Genome envisions a world in which accessing dental literacy is personalized and easy to all. Oral Genome is developing a science-based at-home dental wellness technology that will help uncover a patients oral health needs and deliver personalized recommendations based on a few drops of saliva. Oral Genome was formed to advance early intervention methods to prevent dental problems.

To learn more about Oral Genome, visit http://oralgenome.com/
Oral Genome Linkedin Page: https://www.linkedin.com/company/oralgenome/

Contact:
Tina Saw, Chief Executive Officer
360-349-0790
https://www.linkedin.com/in/drtinasaw/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.